AMENDMENTS

In the specification

Please amend the specification by deleting the term "said" from line 2 of the Abstract. A new abstract is attached to this response.

In the claims

Please amend the claims as follows, without prejudice or disclaimer:

5. An isolated nucleic acid molecule encoding an immunogenic peptide derived from prostate-specific antigen, the peptide being capable of eliciting an immune response for treating prostate cancer and consisting of an amino acid sequence as defined by Formula I:

X_n-X_1-X-X-X-X-X-X-X-X_2

wherein

n=0 or 1 ;

each X_1 is independently selected from leucine or methionine;

each X_2 is independently selected from valine or leucine; and

each X is independently selected from any amino acid,

and fragments, elongations, analogs or derivatives of the PSA derived peptides.

6. (Amended) An isolated nucleic acid encoding a PSA derived peptide according to claim 5 comprising:

a) the nucleic acid sequence as shown in any one of SEQ ID NOS.:7-9 wherein T may also be U;

b) a nucleic acid sequence that is complementary to a nucleic acid sequence of (a);

c) a nucleic acid sequence that has at least 90% homology to a nucleic acid sequence of (a) or (b);

d) a nucleic acid sequence that is an analog of a nucleic acid sequence of (a), (b), or (c); or

e) a nucleic acid sequence that hybridizes to a nucleic acid sequence of (a), (b), (c), or (d) under stringent hybridization conditions.

B3 9. (Amended) An isolated host cell transformed with an expression vector of claim 8.

B4 20. (Amended) A method of treating prostate cancer comprising administering to an animal an effective amount of a peptide in accordance with claim 5.